PDCD1 and glioblastoma: Antagonizing or blocking PD-1 and CTLA-4 are well-recognized FDA-approved anticancer strategies aimed at improving T-cell function in multiple malignancies, including melanoma and non-small-cell lung carcinoma; however, these strategies have shown only limited efficacy in GBM [120,121].